GMT GPW Periodic report · PAP Biznes
Genomtec SA (GMT) · Q1 2026 results
Share price: 2.66 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 1 Jun 2026 and 29 May 2025
Net loss narrowed year on year. The language turned more cautious.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss narrowed
Net income vs Q1 2025
Net income -2.2M vs -3.2M
Revenue −56.0%
2 · How the report reads
More cautious
Language tone vs last period
Report language: typical for a company report — more cautious than in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Fading
The company developed technology and mobile diagnostic equipment based on a lab-on-a-chip solution to detect infectious diseases for 8,908 thousand.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
2.66 zł
close of 2026-11-10
Revenue growth, 3 years
−19.3% a year
compound annual rate (CAGR)
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Typical for a company report — more cautious than in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Full figures
PLN · PAP Biznes report (2026-06-01)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 22.0K | 50.0K | −56.0% |
| Operating income | -2.1M | -3.1M | Loss narrowed |
| Net income | -2.2M | -3.2M | Loss narrowed |
| EPS | -0.15 | -0.22 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- Fading The fair value of financial instruments held by the Group on respective balance sheet dates did not differ significantly from the values…
- 2,000,000 shares, the issue price of which will be determined by the Management Board based on market conditions, corresponding to the…
- In the Company and adopted a resolution regarding the issuance of subscription warrants with the right to subscribe for shares, a…
Faded since Q1 2025
- Dropped Development of a mobile diagnostic device based on a lab-on-chip solution for the detection of COVID-19 (SARS-CoV-2 virus)
- Fading The same accounting principles and calculation methods were applied in the preparation of the quarterly condensed financial statements.
Latest announcements
Official filings, newest first.
- Half-year report · ESPI periodic
- Zawiadomienie o zmianie stanu posiadania akcji Spółki · ESPI 43/2026
- Zawiadomienie o zmianie stanu posiadania akcji Spółki · ESPI 42/2026
- Zawiadomienie o zmianie stanu posiadania akcji Spółki · ESPI 41/2026
- Powiadomienie notyfikacyjne otrzymane od Prezesa Zarządu w trybie art. 19 ust. 1. Rozporządzenia MAR · ESPI 40/2026
- Otrzymanie informacji o udzieleniu ochrony patentowej w USA oraz rejestracji znaku towarowego w UE. · ESPI 39/2026
- Uzupełnienie informacji nt. nowego członka Rady Nadzorczej GENOMTEC S.A. · ESPI 38/2026
- Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Genomtec S.A. · ESPI 37/2026